富瑞:維持歐舒丹(0973.HK)“買入”評級 目標價21.9港元
富瑞發佈研究報告,維持歐舒丹(0973.HK)“買入”評級 ,目標價21.9港元。
歐舒丹第三財季銷售淨額按報告匯率計算增長17.9%,按固定匯率計算增長15.2%。
富瑞稱,主要因歐舒丹品牌的健康增長、旗下品牌 Elemis 今年銷售增長不足,但仍是不錯的雙位數增長,且公司2020年中期開始打入中國市場及發展增長。根據2020年首9個月的趨勢,該行認為歐舒丹今年的整體收入增長19%目標大致符合預期。按品牌劃分,LOccitane en Provence 的銷售趨勢有所改善,但被其他品牌的不足有所抵消。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.